Key result
Weight-based enoxaparin achieves therapeutic prophylactic anti-factor Xa levels in an extremely underweight elderly patient.
Why the study?
There is little evidence for optimal anticoagulation dosing for VTE prophylaxis in adult patients weighing under 40 kg, particularly regarding achieving therapeutic anti-factor Xa levels at extreme low weights.
Does weight-based dosing of enoxaparin achieve therapeutic prophylactic anti-factor Xa levels in an extremely underweight elderly patient?
Does weight-based dosing of enoxaparin achieve therapeutic prophylactic anti-factor Xa levels in an extremely underweight elderly patient?
Weight-based dosing of enoxaparin can successfully achieve therapeutic prophylactic anti-factor Xa levels in extremely underweight elderly patients.
Answers are grounded in this paper and cite their sources.
May be reasonable in extremely underweight elderly; hypothesis-generating case report that should not yet change practice.
A review of the literature revealed little evidence for optimal anticoagulation dosing for VTE prophylaxis in adult patients weighing under 40 kg. Various adjustment strategies have been utilized; however, there is no available evidence pertaining to patients at the extreme of low weight represented by the reported case or to attainment of an anti-factor Xa level within the therapeutic range in such patients. This case represents the use of a weight-based enoxaparin strategy for an extremely underweight elderly patient and the attainment of a therapeutic prophylactic anti-factor Xa level.
No takes yet. Share an insight, caveat, or question.
Lanier et al. (2026) studied this question. Weight-based dosing of enoxaparin successfully achieved a therapeutic prophylactic anti-factor Xa level in an extremely underweight elderly patient.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: